Variable name | High adherence | Moderate adherence | High-then-poor adherence | Delayed-poor adherence | Early-poor adherence | Total | P-value |
---|---|---|---|---|---|---|---|
Sample size, n (%) | 781 (43.4) | 202 (11.2) | 190 (10.6) | 255 (14.2) | 370 (20.6) | 1,798 (100.0) | Â |
Any nintedanib discontinuation (yes/no), mean (sd) | 0.6% (8.0%) | 37.6% (48.6%) | 55.3% (49.9%) | 98.0% (13.9%) | 100.0% (0.0%) | 44.8% (49.7%) | < 0.001 |
Any pirfenidone use (yes/no), mean (sd) | 0.9% (9.4%) | 1.5% (12.1%) | 14.7% (35.5%) | 22.4% (41.7%) | 18.6% (39.0%) | 9.1% (28.8%) | < 0.001 |
Any pirfenidone use conditional on nintedanib discontinuation (yes/no), mean (sd) | 0.0% (0.0%) | 1.3% (11.5%) | 21.9% (41.6%) | 22.8% (42.0%) | 18.6% (39.0%) | 18.6% (38.9%) | < 0.001 |
PDC | Â | Â | Â | Â | Â | Â | Â |
 Nintedanib, mean (sd) | 0.961 (0.043) | 0.712 (0.145) | 0.738 (0.112) | 0.364 (0.103) | 0.127 (0.055) | 0.653 (0.343) | < 0.001 |
 Pirfenidone, mean (sd) | 0.000 (0.005) | 0.001 (0.008) | 0.012 (0.032) | 0.025 (0.056) | 0.024 (0.063) | 0.010 (0.039) | < 0.001 |
 Nintedanib + pirfenidone, mean (sd) | 0.961 (0.043) | 0.713 (0.145) | 0.750 (0.112) | 0.389 (0.116) | 0.151 (0.085) | 0.663 (0.335) | < 0.001 |